Meet with the people who are leading efforts to improve the quality and efficiency of our healthcare system. Talk with thought leaders who craft policy at the state and federal level. Engage with life sciences entrepreneurs who are discovering and commercializing products that can extend and improve our lives.
The Colloquium in Healthcare Leadership brings prominent leaders from public, private, and nonprofit healthcare organizations to campus for candid discussions. You will deepen your understanding of the major trends in healthcare as well as the challenges of being a leader in this space.
Thursday Evening Series - 6:30 PM, PARK STREET AUDITORIUM, 55 PARK STREET
Due to University and Public Health Guidance on meetings and gatherings, in-person attendance is restricted to students who are required by their program to enroll in this course. All others are welcome to audit virtually only. Contact Judi.Gargiulo@Yale.edu to request receipt of the weekly Zoom invite.
September 2, 2021, 7:00 p.m.
Introduction to the Thursday Evening Colloquium
Howard P. Forman, MD, MBA, Professor of Radiology & Public Health (Health Policy), Director, YSPH Health Care Management Program, Director, MD/MBA Program, Faculty Director, Executive MBA Program (Healthcare) Details
Professor Forman is a Professor of Diagnostic Radiology (and faculty director for Finance), Public Health (Health Policy), Economics and Management. Professor Forman directs the Health Care management program in the Yale School of Public Health and teaches healthcare economics in the Yale College Economics Department. He is the faculty founder and director of the MD/MBA program as well as the faculty director of the healthcare focus area in the School of Management’s MBA for Executives program. He is the co-founder and special advisor to the Pozen-Commonwealth Fund Fellowship in Health Equity Leadership program. He co-hosts the Health & Veritas podcast with Dr. Harlan Krumholz.
As a practicing emergency/trauma radiologist, he is actively involved in patient care and issues related to financial administration, healthcare compliance, and contracting. His research has been focused on improving imaging services delivery through better access to information. He has worked as a health policy fellow in the U.S. Senate, on Medicare legislation.
During the COVID Pandemic, Professor Forman has actively tracked outbreaks at local, national, and international levels; expounding on mitigation strategies and engaging to dispel misinformation through social and print media. He has been a frequent guest commentator and expert on national video and audio platforms.
September 30, 2021
Victoria Veltri, JD, LLM, Executive Director, State of CT Office of Health Strategy
Victoria Veltri, JD, LLM, is the Executive Director of the State of Connecticut Office of Health Strategy, appointed to serve as the first head of this agency in February 2018. She was reappointed by Governor Ned Lamont in 2019 to oversee the office’s mission to implement comprehensive, data driven strategies that promote equal access to high quality health care, control costs and ensure better health for the people of Connecticut.
Under her leadership, the office thus far has:
- Developed the five-year strategic plan with stakeholders
- Developed the Connecticut Healthcare Affordability Index
- Incorporated the first cost caps for hospital and hospital system mergers and acquisitions to contain health care price growth
- Launched the Connecticut Health Information Exchange
- Implemented Executive Order No. 5 to develop cost growth and quality benchmarks and primary care spending targets and delivery reforms
- Implemented Community Health Worker (CHW) Advisory Board to advise DPH on the creation of certification and training standards for CHWs
- Launched the Covered Connecticut Program
Ms. Veltri participates in the National Academy of State Health Policy (NASHP) State Leaders Work Group on Hospital and Health System Costs, the New England States Consortium Systems Organization (NESCSO) ongoing work groups on regional opportunities for state government in health care oversight and regulation. She is a Milbank Memorial Fund Fellow.
From 2016 to 2018, she was the Chief Health Policy Advisor in the Office of Lt. Governor Nancy Wyman, coordinating the state’s health reform initiatives, including the State Innovation Model Initiative, the Health Care Cabinet and other initiatives. She acted as the Lt. Governor’s liaison on health care issues with state agencies, community organizations and the private sector.
She is a member of the Board of Directors of the Connecticut Health Insurance Exchange (d/b/a Access Health CT), and previously served as a member of the Board of Directors of Connecticut Partners for Health. Ms. Veltri has extensive legal experience in health care advocacy and in legislative policy and she lectures frequently at colleges, universities and conferences on health reform and Connecticut health care initiatives.
Prior to joining Lt. Governor Wyman’s staff, Ms. Veltri was the state's Healthcare Advocate in the Office of the Healthcare Advocate (OHA). She oversaw OHA in its mission to: assist health insurance consumers with managed care plan selection; educate consumers about their health care rights; directly assist health insurance consumers with filings of complaints and appeals, and; pursue systemic healthcare advocacy.
October 7, 2021
Mary-Ann Etiebet, MD (‘03), MBA (’03), AVP for Health Equity, Merck, Lead, Merck for Mothers
Dr. Mary-Ann Etiebet has two decades of experience improving healthcare outcomes for underserved populations and transforming healthcare delivery at the frontlines. She serves as AVP for Health Equity at Merck and the Lead of Merck for Mothers*, Merck's $500M global health initiative to help create a world where no woman has to die giving life. Since 2011, Merck for Mothers programs and partnerships have resulted in healthy pregnancies and safe deliveries for over 13M women in 50 countries.
Building on her experiences as a physician, researcher, implementer, funder and advocate across the public, private and global development sectors, Dr. Etiebet brings a diverse set of perspectives to advancing health equity. She joined Merck from Premier Inc, where she was a Principal Consultant in the Population Health Management team. Previously, she served as Director of Ambulatory Care Strategies for New York City Health and Hospital. Her work in global health includes serving as the Senior Technical Advisor of the Institute of Human Virology-Nigeria, a PEPFAR implementing partner, while she was Assistant Professor, Division of Infectious Disease at the University of Maryland School of Medicine.
Dr. Etiebet holds an MD and MBA from Yale University. She completed her residency in Internal Medicine at New York-Presbyterian Weill Cornell and fellowship in Infectious Diseases Hospital System at New York-Presbyterian Columbia University Medical Center, becoming Board Certified in both Internal Medicine and Infectious Diseases. She is a member of the Center for Global Development Board of Directors, the Board of Trustees of Vital Strategies, and the Advisory Committee for the Pozen-Commonwealth Fund Fellowship in Health Equity Leadership at Yale University. She also serves as the private sector representative on the World Health Organization (WHO) hosted Partnership for Maternal, Newborn & Child Health Board and the Investors Group of the World Bank’s Global Financing Facility.
*Merck for Mothers is known as MSD for Mothers outside of the U.S. and Canada
October 28, 2021
Stephen Knight, MD (’90), MBA (’90), President & Managing Partner, F-Prime Capital
Stephen Knight joined F-Prime Capital in 2003 where he serves as President and Managing Partner. He has worked in the pharmaceutical and biotechnology industries for over 25 years and invests broadly across healthcare. Steve serves on the Board of Directors of Atalanta Therapeutics, Ensoma, Genomics plc, Leyden Labs, Prime Medicine, Proof Diagnostics, Pulmocide and Skyline Therapeutics. Steve previously served on the boards of several private and public health care companies including Beam Therapeutics (NASDAQ: BEAM), Blueprint Medicines (NASDAQ: BPMC), Denali Therapeutics (NASDAQ: DNLI), FoldRx Pharmaceuticals (acquired by Pfizer), Innovent Biologics (1801.HK), Iora Health (acquired by One Medical), Ironwood Pharmaceuticals (NASDAQ: IRWD), NextWave Pharmaceuticals (acquired by Pfizer), Proteostasis Therapeutics (NASDAQ: PTI), Respivert, Ltd (acquired by J&J), Sana Biotechnology (NASDAQ: SANA) and Semma Therapeutics (acquired by Vertex).
Prior to joining F-Prime Capital, Steve held various senior management roles in private and public biotechnology and consulting companies. He also was a researcher at AT&T Bell Laboratories, the National Institutes of Health, and Yale University. He holds an M.D. from the Yale University School of Medicine, an M.B.A. from the Yale School of Organization and Management and received a B.S. in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa.
November 4, 2021
Suzanne Lagarde, MD, MBA (’14), FACP, CEO, Fair Haven Community Health Care
Dr. Lagarde currently serves as CEO of Fair Haven Community Health Care (FHCHC), a Federally Qualified Health Center providing comprehensive healthcare to over 28,000, primarily low income, minority patients. In this role, she oversees a staff of nearly 300 who provide care at 14 locations throughout southern CT. In her 8 years at the helm of FHCHC, she has overseen considerable growth, with the addition of several new clinical sites and new clinical services. Under her leadership, FHCHC has been nationally recognized for its high quality care, being honored with HRSA’s Health Quality Leader Award for the past 5 consecutive years.
Trained as a gastroenterologist, Dr. Lagarde was a founding member of CT Gastroenterology Consultants, a large private practice in southern CT where she worked for many years prior to her current position. She is an Assistant Clinical Professor of Medicine at Yale University and attending gastroenterologist at Yale New Haven Hospital. She graduated summa cum laude with a degree in mathematics from Fordham University and obtained her medical degree from Cornell University. She acquired her MBA, specializing in Healthcare, from Yale University.
Dr. Lagarde is a founding member and past president of Project Access-New Haven, a non-profit which provides access to specialty care for the uninsured. She has devoted her career to improving health care for the underserved. Following Hurricane Katrina, Dr. Lagarde obtained a license to practice medicine in Mississippi. For 5 years through 2012, she travelled quarterly to rural Mississippi where she donated her services to the indigent patients of a large FQHC, Coastal Family Health. In acknowledgement of her many contributions, she has received numerous community service awards, among them the “Healthcare Leadership and Innovator Award” from the Connecticut State Medical Society, one of the medical society’s highest recognitions.
Dr. Lagarde advocates for the underserved at city, state and national levels. She has served on many key committees, including the Steering Committee of CT SIM (State Innovation Model) charged with healthcare reform in the state of CT. She currently serves on the Medical Assistance Program Oversight Council (MAPOC) for the state of CT, the agency with direct oversight of the Medicaid Program in CT. She has served on the Ambulatory Care Accreditation Advisory Council of The Joint Commission, the sole representative of FQHCs nationwide. She chairs the Board of Directors of The Connecticut Hospice in Branford CT and serves as the Vice-Chair of the Board of Directors of Community Health Network (CHN), the Ambulatory Services Organization (ASO) for CT Medicaid medical. She is committed to practice transformation and currently serves on the Alternate Payment Methodology committee of the Community Health Center Association of CT.
November 18, 2021
Martin Mackay, Ph.D., Co-Founder and Chief Executive Officer, Rallybio
Martin, a veteran for 30 years, is currently the CEO and co-founder of Rallybio, formed to develop transformative therapies for patients with devastating ultra-rare diseases. He was Head of R&D at Alexion where launches included Strensiq and Kanuma in addition to a new indication for Soliris. Previously, he was Head of R&D at AstraZeneca and launches included Brilinta, Farxiga and Caprelsa. At Pfizer, he led the R&D organization as the company prepared to launch Xeljanz, Xalkori and Eliquis and other launches included Selzentry, Chantix, Sutent and Lyrica.
Martin obtained a First-Class Honours degree from Heriot-Watt University and his PhD from the University of Edinburgh. His postdoctoral work was conducted at the University of Edinburgh. Martin is a Board member of Charles River Laboratories, Novo Nordisk and is a Senior Advisor to New Leaf Venture Partners.
December 2, 2021
Keith Churchwell, MD, President, Yale New Haven Hospital
Keith B. Churchwell, MD, FACC, FAHA, FACP is the President of Yale New Haven Hospital and Associate Clinical Professor of Medicine at Yale School of Medicine. He held the previous positions of Executive Vice President and Chief Operations Officer and Senior Vice President and Executive Director for Heart & Vascular Services, Transplantation Services and Clinical Service Coordinator for the Department of Medicine at Yale New Haven Hospital.
Born and raised in Nashville, Tennessee he obtained his undergraduate degree from Harvard University and medical degree from Washington University School of Medicine. He spent his formative training years at Emory University Medical School and Affiliated Hospitals, then spending 12 years in private cardiology practice before joining Vanderbilt Medical School as full-time academic faculty in 2006 (he became a member of the clinical faculty at Vanderbilt in 1999). At Vanderbilt he was an Associate Professor of Medicine and Radiology and the Executive Director/Chief Medical officer the Vanderbilt Heart and Vascular Institute from 2009-14. Dr. Churchwell is also on the National Board of the American Heart Association and is the Chair of the National Advocacy Committee for AHA through 2021. He sits on a number of local boards on the New Haven area including President of the New Haven Symphony Board, Columbus House and the New England Donor Services.
January 27, 2022 (virtual due to Covid-19 restrictions)
Guy Fish, (’85), MBA (‘94), President and CEO, Greater Lawrence Family Health Center
Guy Fish, MD, MBA, has extensive health care experience as a physician and a consultant in numerous executive leadership roles which encompass both the for-profit and nonprofit health care sectors. Before joining GLFHC in July 2021, Fish was acting CEO of Nextstage Therapeutics, a Spanish company with exosome technologies. Prior to that, he was CEO of Cellanyx Diagnostics, which uses artificial intelligence to predict which cancers are aggressive and which are not. Before Cellanyx, Fish was a leader with profit and loss responsibilities for 17 years at the health care strategy consulting firm Fletcher Spaght, Inc. His market assessments, due diligence in acquisitions, fundraising, and strategic growth planning for a wide range of medical services and products resulted in substantial value creation over the last ten years. In the nonprofit sector, Fish is Chairman of the Board of Trustees at health care think-tank Altarum Institute which is focused on improving the health of marginalized communities. As treasurer of the Harvard Alumni Association, he spearheaded initiatives to advance social justice and anti-racism. Fish is also a Lay Trustee of the Beth Israel Deaconess Medical Center and has chaired both the Patient Care Committee and the Medical Education Committee.
February 3, 2022 (virtual due to Covid-19 restrictions)
Gil Addo (YC’07), MBA, Co-Founder & CEO, RubiconMD, Inc.
Gil Addo is CEO and Co-founder of RubiconMD, a wholly-owned subsidiary of Oak Street Health. RubiconMD’s digital health platform empowers primary care clinicians with access virtual specialty care from top medical specialists to improve patient care.
Founded in 2013, RubiconMD serves primary care clinicians across 37 states. The Huffington Post named RubiconMD one of the “Five Companies Defining the Future of Healthcare” and, in 2020, AllianceBernstein ranked RubiconMD number 12 on its list of the top 25 private companies disrupting healthcare. Prior to founding RubiconMD, Gil was a Consultant at Putnam Associates, a pharma strategy consultancy, where he designed payer and market access strategies for fortune 500 clients. He previously held strategy and business development roles at Xerox, Cubist (acquired by Merck), and two early stage healthcare ventures.
Gil has appeared in Inc, Forbes, CNBC, Fortune and Entrepreneur Magazine. He’s been named one of Forbes’ “30 Under 30” in healthcare, Crains New York Business 40 Under 40 and Business Insider’s 30 under 40 in healthcare. In 2020, Crains New York named Gil to its list of the Most Notable in Health Care and in 2017 he received their Heritage Healthcare Innovator of the Year award. He holds a BS in Economics and Biomedical Engineering from Yale and an MBA from Harvard.
February 17, 2022
Marc Rothman, MD, Chief Medical Officer & Adam McAnaney, JD, General Counsel and Secretary, Signify Health
Marc Rothman, MD, has served as Chief Medical Officer of Signify Health since June 2020. Prior to joining Signify, Dr. Rothman served as Deputy Chief Medical Officer at Aspire Healthcare, where he led a nationwide palliative care medical practice and implemented and grew new clinical models and business lines. He also served as Enterprise Chief Medical Officer at Kindred Healthcare, Inc., where he oversaw medical affairs, clinical quality, patient experience and pharmacy services. Additionally, he served as the Chief Medical Officer of Kindred’s Nursing Center Division, leading the medical and pharmacy leadership team.
Dr. Rothman holds an MD from New York University School of Medicine and a BA in Philosophy from the University of Wisconsin, Madison. He completed his postgraduate clinical training at Yale New Haven Hospital and is triple boarded in Internal, Geriatric and Hospice & Palliative Medicine.
Adam McAnaney, JD, has served as General Counsel and Secretary of the Company since its acquisition of Remedy Partners in November 2019. He joined Remedy Partners as General Counsel and Secretary in June 2019. Prior to joining Remedy Partners, Mr. McAnaney was at Aetna where he served as Vice President, Head of Corporate Legal and Corporate Secretary from November 2017 to March 2019, overseeing legal support of SEC reporting and disclosure matters, corporate finance, mergers and acquisitions, subsidiary management, licensing, investments, executive compensation and human resources. Mr. McAnaney previously held the positions of Senior Corporate Counsel from May 2013 to October 2017 and Counsel from May 2011 to April 2012 at Aetna. From September 2004 to May 2011, he was an Associate in the New York, Frankfurt and London offices of Sullivan & Cromwell LLP focusing on capital markets and mergers and acquisitions.
Mr. McAnaney holds a JD from Columbia Law School and a BA in Germanic Languages and Literatures from Yale University.
March 3, 2022
Matthew Comerford, MBA, Senior Vice President, Chief Strategy Officer, Office of Strategy Management, Yale New Haven Hospital
Joined by Brittany Blau, MPH, and Greg Pfeiffer, MPH.
Matthew Comerford is the Chief Strategy Officer of Yale New Haven Health System, and Senior Vice President and Managing Director of the Internal Consulting Group (within the Office of Strategy Management) at Yale New Haven Health (YNHH). Matthew currently has over eight years of experience within the health system. His areas of responsibility consist of strategy development, including corporate, service line, and exploratory strategies, as well as organizational design, performance management, and cost reduction strategies within the Internal Consulting Group.
Matthew has over twenty-five years of prior management consulting experience that focuses on working with C-level executives to address a variety of strategic, organizational, and transformational issues. Experiences include strategy development and articulation, strategic repositioning, strategic cost reduction, developing growth agendas, pre and post transaction advisory and large-scale multi-functional transformation. Matthew has a cross industry background including experience working with payers, medical device companies, and provider organizations. At OSM, Matthew leads 50 individuals supporting our executive team with system-wide initiatives.
Brittany Blau started her healthcare career as a care manager in assisted livings where she saw first-hand the disconnect between healthcare organizations and the challenge this disconnect created for patients and their care givers. With this experience in mind, Brittany pursued an MPH in Healthcare Management from the Yale School of Public Health, graduating in 2016. She then spent three years in Baker Tilly’s Healthcare Consulting practice supporting health systems with community health needs assessments and medical device manufacturers with health economic analyses, market research, and developing advisory councils.
In 2018 Brittany joined the Office of Strategy Management (OSM) at Yale New Haven Health, where she is now a Senior Consultant. In this role, Brittany works with executives across the System to drive initiatives in organizational design, integration, and change management. She was a key member of the integration team for the acquisition of Milford Hospital in June of 2019. More recently, Brittany developed the change management capability within OSM and is working with System executives to design a future state organizational model for the System. Brittany is also responsible for the management of the OSM, which includes developing talent, project scoping and resourcing, advancing OSM capabilities, and leading our Talent Management Strategy.
Greg Pfeiffer graduated from the Yale School of Public Health with an MPH in Healthcare Management and from the Yale School of Divinity with an M.A.R.c in Ethics in 2017. He joined the Strategic Planning team at Yale New Haven Health System and was an Inaugural member of the Office Of Strategy Management (OSM) when it was merged with the Internal Consulting Group (ICG) and Business Development team in 2018. As a manager in the OSM’s Corporate Strategy team, he supports key priorities from the health system’s Multiyear Strategy, including USN&WR ranking optimization, Academic Health System strategy, Ambulatory strategy, and Service Line strategy. One thing Greg loves about his job is the opportunity to work with physicians who are at the top of their field, contributing to truly innovative and lifesaving healthcare.
April 7, 2022
Nneka Mobisson, MD (’04), MBA (’04), MPH, Co-founder and CEO, mDoc.com
Dr. L. Nneka Mobisson is co-founder and CEO of mDoc. Prior to mDoc, Dr. Mobisson was Executive Director, Africa at the Institute for Healthcare Improvement (IHI) where she still serves as faculty advisor.
A pediatrician, Dr. Mobisson was Vice President of Community Health and Population Health Management at Connecticut Hospital Association. At McKinsey & Company, she worked primarily on healthcare strategy. She has worked at World Bank, Merck and Co., and the CDC.
Dr. Mobisson earned a bachelor's in Mechanical Engineering from MIT, MPH from Emory, MD/MBA from Yale and completed her Pediatrics residency at Children's Hospital of Philadelphia. She is an Ashoka and Making More Health Fellow, a Forbes Africa New Wealth Creator, a Cartier Awards Finalist, a WEF Young Global Leader, and a Yale Associate World Fellow.